Your browser doesn't support javascript.
loading
Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort.
Zeinomar, Nur; Phillips, Kelly-Anne; Daly, Mary B; Milne, Roger L; Dite, Gillian S; MacInnis, Robert J; Liao, Yuyan; Kehm, Rebecca D; Knight, Julia A; Southey, Melissa C; Chung, Wendy K; Giles, Graham G; McLachlan, Sue-Anne; Friedlander, Michael L; Weideman, Prue C; Glendon, Gord; Nesci, Stephanie; Andrulis, Irene L; Buys, Saundra S; John, Esther M; Hopper, John L; Terry, Mary Beth.
Afiliação
  • Zeinomar N; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY.
  • Phillips KA; Centre for Epidemiology and Biostatistics, The University of Melbourne, Parkville, VIC, Australia.
  • Daly MB; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Milne RL; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
  • Dite GS; Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA.
  • MacInnis RJ; Centre for Epidemiology and Biostatistics, The University of Melbourne, Parkville, VIC, Australia.
  • Liao Y; Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, VIC, Australia.
  • Kehm RD; Centre for Epidemiology and Biostatistics, The University of Melbourne, Parkville, VIC, Australia.
  • Knight JA; Centre for Epidemiology and Biostatistics, The University of Melbourne, Parkville, VIC, Australia.
  • Southey MC; Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, VIC, Australia.
  • Chung WK; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY.
  • Giles GG; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY.
  • McLachlan SA; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.
  • Friedlander ML; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
  • Weideman PC; Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Parkville, VIC, Australia.
  • Glendon G; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY.
  • Nesci S; Department of Pediatrics and Medicine, Columbia University, New York, NY.
  • Andrulis IL; Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, VIC, Australia.
  • Buys SS; Department of Medicine, St Vincent's Hospital, The University of Melbourne, Parkville, VIC, Australia.
  • John EM; Department of Medical Oncology, St Vincent's Hospital, Fitzroy, VIC, Australia.
  • Hopper JL; Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia.
  • Terry MB; Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW, Australia.
Int J Cancer ; 145(2): 370-379, 2019 07 15.
Article em En | MEDLINE | ID: mdl-30725480
Benign breast disease (BBD) is an established breast cancer (BC) risk factor, but it is unclear whether the magnitude of the association applies to women at familial or genetic risk. This information is needed to improve BC risk assessment in clinical settings. Using the Prospective Family Study Cohort, we used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association of BBD with BC risk. We also examined whether the association with BBD differed by underlying familial risk profile (FRP), calculated using absolute risk estimates from the Breast Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) model. During 176,756 person-years of follow-up (median: 10.9 years, maximum: 23.7) of 17,154 women unaffected with BC at baseline, we observed 968 incident cases of BC. A total of 4,704 (27%) women reported a history of BBD diagnosis at baseline. A history of BBD was associated with a greater risk of BC: HR = 1.31 (95% CI: 1.14-1.50), and did not differ by underlying FRP, with HRs of 1.35 (95% CI: 1.11-1.65), 1.26 (95% CI: 1.00-1.60), and 1.40 (95% CI: 1.01-1.93), for categories of full-lifetime BOADICEA score <20%, 20 to <35%, ≥35%, respectively. There was no difference in the association for women with BRCA1 mutations (HR: 1.64; 95% CI: 1.04-2.58), women with BRCA2 mutations (HR: 1.34; 95% CI: 0.78-2.3) or for women without a known BRCA1 or BRCA2 mutation (HR: 1.31; 95% CI: 1.13-1.53) (pinteraction = 0.95). Women with a history of BBD have an increased risk of BC that is independent of, and multiplies, their underlying familial and genetic risk.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Mamárias / Neoplasias da Mama Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Mamárias / Neoplasias da Mama Idioma: En Ano de publicação: 2019 Tipo de documento: Article